Clinical Trial Update: An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old [Phase 4]

View source ↗

Summary

An open-label Phase 4 trial evaluating deferasirox in Chinese children aged 2 to less than 6 with beta-thalassemia major has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: β-thalassemia Major | Phase 4 | Status: WITHDRAWN